Monil Shah

Monil Shah, PharmD, MBA, is Senior Advisor, Clinical Development At Brooklyn ImmunoTherapeutics. Previously, he was Chief Operating Officer at IRX Therpeutics and has over 18 years of pharmaceutical and biotechnology industry experience in oncology drug development. Prior to joining IRX Therapeutics, Dr. Shah was the Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb. Dr. Shah was Head of Clinical Operations and Development at Ventrus Biosciences prior to its merger with Assembly Biosciences. Prior to Ventrus, Dr. Shah led the solid tumor development programs and led the clinical portfolio and strategic planning function at Celgene Corporation. He led the Oncology Development and Operations activities at Fibrogen and Novacea. Dr. Shah began his career at Novartis in the Oncology Early Development Group leading clinical trials prior to joining the Medical Sciences Group at Amgen. Dr. Shah received his BS and PharmD degrees from Rutgers, The State University of New Jersey and his MBA from Florida Institute of Technology.